Recombinant Human Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 (LGR5) Protein (His)

Name: Recombinant Human Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 (LGR5) Protein (His)
Brand: Beta LifeScience
SKU: BLC-08209P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Based on the SEQUEST from database of Yeast host and target protein, the LC-MS/MS Analysis result of this product could indicate that this peptide derived from Yeast-expressed Homo sapiens (Human) LGR5.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 (LGR5) Protein (His) is produced by our Yeast expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	O75473
Target Symbol	LGR5
Synonyms	FEX; G protein coupled receptor 49; G protein coupled receptor 67; g protein-coupled receptor fex; G-protein coupled receptor 49; G-protein coupled receptor 67; G-protein coupled receptor HG38; GPCR GPR49; GPR 49; GPR 67; GPR49; GPR67; GRP 49; GRP49; HG 38; HG38; Leucine rich repeat containing G protein coupled receptor 5 ; Leucine-rich repeat-containing G-protein coupled receptor 5; LGR 5; LGR5; LGR5_HUMAN; MGC117008; Orphan G protein coupled receptor HG38
Species	Homo sapiens (Human)
Expression System	Yeast
Tag	N-6His
Target Protein Sequence	GSSPRSGVLLRGCPTHCHCEPDGRMLLRVDCSDLGLSELPSNLSVFTSYLDLSMNNISQLLPNPLPSLRFLEELRLAGNALTYIPKGAFTGLYSLKVLMLQNNQLRHVPTEALQNLRSLQSLRLDANHISYVPPSCFSGLHSLRHLWLDDNALTEIPVQAFRSLSALQAMTLALNKIHHIPDYAFGNLSSLVVLHLHNNRIHSLGKKCFDGLHSLETLDLNYNNLDEFPTAIRTLSNLKELGFHSNNIRSIPEKAFVGNPSLITIHFYDNPIQFVGRSAFQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNLLEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLTGNHALQSLISSENFPELKVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLLDFEEDLKALHSVQCSPSPGPFKPCEHLLDGWLIR
Expression Range	22-561aa
Protein Length	Partial
Mol. Weight	62.4kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development.
Subcellular Location	Cell membrane; Multi-pass membrane protein. Golgi apparatus, trans-Golgi network membrane; Multi-pass membrane protein.
Protein Families	G-protein coupled receptor 1 family
Database References	HGNC: 4504 OMIM: 606667 KEGG: hsa:8549 STRING: 9606.ENSP00000266674 UniGene: Hs.658889
Tissue Specificity	Expressed in skeletal muscle, placenta, spinal cord, and various region of brain. Expressed at the base of crypts in colonic and small mucosa stem cells. In premalignant cancer expression is not restricted to the cript base. Overexpressed in cancers of th

Gene Functions References

Data conclude that LGR5 expression in CTCs may serve as a marker for CRC metastasis. PMID: 29949050
LGR5 is a new functional GSC marker and prognostic indicator that can promote EMT by activating the Wnt/beta-catenin pathway and would thus be a novel therapeutic target for glioma. PMID: 30208924
Data found LGR5 as a potential target of miR-340. LGR5 was highly expressed in breast cancer cells. Relative expression of LGR5 was negatively regulated by miR-340. Knockdown of LGR5 also inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. PMID: 30300682
knockdown of CASC15 significantly inhibited the proliferation, migration and invasion of colon cancer cells in vitro and in vivo. Following mechanistic experiments, CASC15 was observed to act as a sponge to suppress microRNA (miR)4310 that targeted LGR5. PMID: 29956772
LGR5 overexpression was associated with high T stage and LN metastasis status in breast cancer. High LGR5 expression was also associated with reduced relapse-free survival, indicating that LGR5 may represent a promising prognostic marker for breast cancer patients. PMID: 29471794
LGR5 is a critical effector of DDX1 in colorectal cancer cells. PMID: 29869821
Logarithmic expansion of LGR5-expressing cells was observed in human colorectal cancer. PMID: 28958617
Our findings indicated that the Lgr5High/DCLK1High expression pattern may be considered as a signature phenotype for intestinal subtypes of gastric carcinoma. PMID: 28946555
Findings suggest a tumor suppressor role for miR-216a in gliomas, which inhibits glioma cell proliferation, migration, and invasion by targeting LGR5. PMID: 28256193
LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer. PMID: 28880275
LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, there were correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (DKK4) and SPARC-related modular calcium binding 2 (SMOC2 PMID: 29467240
LGR5 expression is transiently upregulated during the early stage of cardiomyocyte differentiation from hPSCs, and although LGR5 expression is not required for maintaining hPSCs in the undifferentiated state, knockdown of LGR5 leads to decreased expression of key cardiac transcription factors at the early stage with eventual lack of robust beating cardiomyocytes at the late stage. PMID: 28793247
Lgr5 plays important roles in angiogenesis. Lgr5-specific siRNA could be designed into an effective therapeutic agent to inhibit gastric cancer angiogenesis. PMID: 28404940
A regulatory mechanism of LGR5 expression in gastric carcinogenesis, with SP1 as an important component of the transcriptional complex and LGR5 activity, which is modulated by its ligands RSPO1 and RSPO2, whose expression is modulated by methylation. PMID: 28219935
these results demonstrate that Lgr5 activation of Wnt/beta-catenin signaling is a potential mechanism to promote the progression of ESCC and ESCC stem cell renewal, and Lgr5 may be used as a molecular target for the development of treatments for ESCC. PMID: 28404917
This study uncovers a novel cross-talk between LGR5 and TGFbeta signaling in colon cancer and identifies LGR5 as a new modulator of TGFbeta signaling able to suppress colon cancer metastasis. PMID: 28939678
Data show that IKKalpha directly bind to the promoters of LGR5, in turn, upregulating LGR5 expression through activation of STAT3 signaling pathway during cancer progression. PMID: 27049829
Report the presence of aberrantly located LGR5(+) cells coexpressing epithelial markers in the stromal compartment of women with endometriosis. These cells have a statistically significantly different expression profile in deep-infiltrating endometriosis in comparison with other types of endometriosis, independent of the menstrual cycle phase. PMID: 28923287
Arrb1 reduced the chemotherapy-induced Lgr5 stem cell apoptosis by inhibiting endoplasmic reticulum stress-mediated mitochondrial apoptotic signaling. PMID: 27195676
LGR5 signaling in gastric cancer cells.LGR5 crosstalk with FOXO1 in gastric cancer cells. PMID: 28970066
High LGR5 expression is associated with osteoarthritis. PMID: 28777797
The LGR5 primarily functions via the IQGAP1-Rac1 pathway to strengthen cell-cell adhesion in normal adult crypt stem cells and colon cancer cells. PMID: 28739799
Lgr5(+) chief cells are involved in maintaining the homeostatic stem cell pool. Define Lgr5(+) chief cells as a major cell-of-origin of gastric cancer. PMID: 28581476
LGR5-expressing fraction of CD54+ cells represents gastric cancer CSCs, in which LGR5 is closely associated with stemness and EMT core genes PMID: 28033430
clathrin-mediated endocytosis inhibition of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness PMID: 28275053
The findings indicated that Lgr5 might contribute to the intestinal metaplasia during gastric carcinogenesis. PMID: 26077638
Endometrial LGR5 is not an endogenous stem cell marker. Instead, LGR5(+) cells appear to be recruited from blood to be part of the stem cell niche at the perivascular microenvironment to activate the endogenous niche. PMID: 27887719
2 LGR5 splice variants were expressed in human intestine crypt cells; one lacked exon 5 and the other lacked exons 5-8. Only LGR5FL appeared during cell cycle arrest. The transcript variants appeared when the cell cycle was proceeding. LGR5FL-positive cells were negative for Ki-67 and were enriched after chemotherapy. PMID: 27140312
Low expression of LGR5 is associated with gastric cancer. PMID: 26386561
Report targeting LGR5+ tumor stem cells with an antibody-drug conjugate as effective treatment for colon cancer. PMID: 26582901
Lgr5 overexpression was significantly associated with deep invasion of colorectal cancer lymphnode metastasis, distant metastasis and AJCC stage PMID: 26758198
Data suggest that targeting of leucine rich repeat containing G protein-coupled receptor 5 (LGR5) may be of therapeutic benefit for neuroblastomas. PMID: 26517508
This study shows that Lgr5 can be a valuable and reliable prognostic factor of colorectal cancer progression. PMID: 26674601
We conclude that overexpression of LGR5 is associated with markers of tumor aggressiveness in human papillary thyroid cancer PMID: 26416247
The results suggest that trichosanthin may induce apoptosis in glioma cells by targeting LGR5 and repressing the Wnt/betabcatenin signaling pathway PMID: 26397053
These findings indicate that LGR5 not only participates in carcinogenesis but also maintained stemness by activating Wnt/b-catenin signaling in breast cancer. PMID: 26086949
We confirmed in a large and independent study cohort that LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-FU-based adjuvant chemotherapy. PMID: 25665511
lgr5 methylation, through the regulation of lgr5 expression and colorectal CSC differentiation, may constitute a novel prognostic marker for colorectal cancer patients. PMID: 26599100
High resolution crystal structure of an ectodomain variant of human LGR5 (hLGR5ecto) complexed with a signalling competent fragment of mouse Rspo2. PMID: 26123262
Lgr5-positive cells may be cancer stem cells-like cells in gastric cancer. PMID: 26279446
Demonstrate the presence of LGR5-positive cells in limbal epithelial crypts and their decrease in inflamed conditions, which suggests a critical role of this protein during inflammation and its possible use as a marker in normal crypts. PMID: 26097379
Elevated Lgr5 expression might contribute to the development and progression of colorectal cancer. PMID: 24751002
data reveal a RSPO2-induced, LGR5-dependent Wnt signaling-negative feedback loop that exerts a net growth-suppressive effect on CRC cells PMID: 24476626
our data highlight a potential role of Lgr5-positive cells in the tumorigenesis of colorectal cancer (CRC), and suggest that treating these Lgr5-positive cells in CRCs may substantially improve the outcome of CRC therapy PMID: 25835970
Lgr5 may play an important role in the development and progression of cervical carcinoma. PMID: 25973068
Based on the lack of correlation between Lgr5 and tested cancer stem cell markers, Lgr5 does not seem to be a potential stemness marker or prognostic factor in pancreatic ductal adenocarcinoma. PMID: 25804119
High LGR5 expression was associated with poor prognosis in patients with colorectal cancer(CRC) and that LGR5 is an efficient prognostic factor in CRC. [meta-analysis; review] PMID: 25192390
we suggest that Musashi-1, Lgr5, and pEGFR are overexpressed in human SIAs and may play roles in human SIA carcinogenesis and progression. PMID: 25773390
the higher expression level of DCLK1 in patients undergoing CRT can propose it as a more relevant candidate among CSC markers comparing to Lgr5 for colorectal cancer patients. PMID: 25631749
increased expression of LGR5 during embryogenesis and the neonatal period alter skin development and homeostasis. PMID: 26003047

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.